Neuromuscular diseases (NMD) such as Dystrophies, Atrophies, Paralysis or Neuropathies are a group of more than 150 genetic illnesses affecting the lower neuromotor system, which include the muscles and nerves system. NMDs share the common traits of childhood onset and progressive muscle weakness, which lead to walk disability, loss of autonomy and psychosocial consequences. There is currently not treatment available to halt the progressive course of these NMDs. Most therapeutic approaches are limited to medicines (by reducing symptoms) and musculoskeletal rehabilitation in-clinic programs, as neurological disorders main feature is the loss of muscles strength and a progressive lack of walking. The key is maintaining walking ability for slowing the deterioration caused by permanent sitting, giving hope for a better and more independent life. Marsi Bionics offers an innovative approach: Wearable Gait Exoskeletons as and effective 24/7 in-house therapy solution for allowing NMD children to walk. ATLAS 2020 is the first paediatric exoskeleton we developed for using in hospitals/rehabilitation centres. Our purpose and why we need and expert in biomechanics is to get ready a more advanced version, ATLAS 2030 for expanding rehabilitation to home and activities of daily living, building a paradigm for NMD rehabilitation. To achieve this goal we are working on providing self-balance capabilities to the exoskeleton. The company is looking for a qualified biomechanical engineer with an excellent background in human locomotion for improving ergonomics and biomechanics of gait balance of our bionics exoskeletons and to analyse the gait dysfunctions from NMD pathologies. The potential Marsi Bionics would achieve improving ATLAS 2030, by accomplishing the ideal ergonomics aspects related to each NMD mobility pattern during the gait by recruiting an expert in Biomechanics, will reinforce research in robotic area for health and will create new market opportunities.

Worlwide, about 60 million people have some kind of difficulty in walking, which is related to some neurological disorder (stroke, dementia, neuromuscular diseases, etc). Roughly 40 million of affected correspond to elders and the % is higher in Europe. The remaining is the sum of physically disabled by cerebral palsy (14 million), neuromuscular diseases (4 million), spinal cord injury (paraplegia and quadriplegia, 3 million) and spina bifida (3 million). Neurological disorders affect the lower motor of the nervous system and share the progressive muscle weakness, which lead to several walk disability, loss of autonomy and psychosocial consequences. Most therapeutic treatments are limited to medicines and musculoskeletal rehabilitation programs, which are very expensive and limited to 15-30 min/week rehabilitation sessions. Active lifestyle is the most effective measure to restore the physical conditions. But the loss of muscle strength impedes the ambulatory function. The need is for a device allowing them walking effortlessly and safely in the everyday life activities. Based on our ARES technology, -the minimal functional unit providing synchronized joints-muscles mobility- Marsi Bionics has developed powered orthoses for in-house rehabilitation of patients affected by muscle weakness disorders, showing a product portfolio that covers the needs of a wide range of Neurological Disorders. Marsi products will be commercialized under renting models allowing patients acquiring it for daily use. This technology will improve these patients life quality and enlarge life expectancy by avoiding critical health complications of losing walking ability. Marsi is strengthened by joining with a leading company in the current industrial market, ESCRIBANO. This alliance in the frame of SME Phase 2 will speed up industrialization, overcome the certification barrier and minimize the time to market. As a result, we expect to reach above 36M€ turnover in 2023 and 81 generated jobs.